COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

The vaccine – developed by researchers at the University of Florida (UF) in the US – is based on mRNA taken from the patient’s tumour that is delivered in a lipid nanoparticle (LNP ...

Mandy Cohen, director of the U.S. Centers for Disease Control and Prevention (CDC), pointed to mRNA as a preferred platform for the shot since vaccines can be developed and distributed quickly.

Five years after the virus that causes COVID emerged in China it still holds some mysteries. The disease has killed an ...

The covid-19 pandemic saw the advent of a revolutionary technology: the first vaccines to be approved that contain messenger RNA (mRNA). The approach helped scientists create vaccines based on ...

Researchers continue to develop new therapies and treatments based on fetal cell lines. In some cases, alternative vaccines may be available, as is the case with the mRNA-based Moderna and Pfizer ...

MRNA) to "hold" from "buy," on declining sales of its COVID-19 vaccine and limited near-term growth prospects. We recently compiled a list of the 10 Stocks That Will Bounce Back According To Hedge ...

Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada Michael Smith Laboratories, University of British Columbia, Vancouver, ...